608 related articles for article (PubMed ID: 25345753)
41. Unmet needs in controlling metabolic disease.
Haffner SM
Rev Cardiovasc Med; 2007; 8 Suppl 4():S17-24. PubMed ID: 17934390
[TBL] [Abstract][Full Text] [Related]
42. The progression of cardiovascular risk to cardiovascular disease.
Rosin BL
Rev Cardiovasc Med; 2007; 8 Suppl 4():S3-8. PubMed ID: 17934392
[TBL] [Abstract][Full Text] [Related]
43. Anti-inflammatory effect of atorvastatin ameliorates insulin resistance in monosodium glutamate-treated obese mice.
Furuya DT; Poletto AC; Favaro RR; Martins JO; Zorn TM; Machado UF
Metabolism; 2010 Mar; 59(3):395-9. PubMed ID: 19800637
[TBL] [Abstract][Full Text] [Related]
44. Impaired glucose tolerance and impaired fasting glucose--a review of diagnosis, clinical implications and management.
Petersen JL; McGuire DK
Diab Vasc Dis Res; 2005 Feb; 2(1):9-15. PubMed ID: 16305067
[TBL] [Abstract][Full Text] [Related]
45. Protection of pancreatic beta-cells: is it feasible?
Bonora E
Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
[TBL] [Abstract][Full Text] [Related]
46. Effects of eicosapentaenoic acid (EPA) treatment on insulin sensitivity in an animal model of diabetes: improvement of the inflammatory status.
Figueras M; Olivan M; Busquets S; López-Soriano FJ; Argilés JM
Obesity (Silver Spring); 2011 Feb; 19(2):362-9. PubMed ID: 20885391
[TBL] [Abstract][Full Text] [Related]
47. Is there a role for immune and anti-in-flammatory therapy in type 2 diabetes?
Sathyapalan T; Atkin SL
Minerva Endocrinol; 2011 Jun; 36(2):147-56. PubMed ID: 21519323
[TBL] [Abstract][Full Text] [Related]
48. Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications.
Pollack RM; Donath MY; LeRoith D; Leibowitz G
Diabetes Care; 2016 Aug; 39 Suppl 2():S244-52. PubMed ID: 27440839
[TBL] [Abstract][Full Text] [Related]
49. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
[TBL] [Abstract][Full Text] [Related]
50. Effect of abdominal obesity on insulin resistance and the components of the metabolic syndrome: evidence supporting obesity as the central feature.
Türkoglu C; Duman BS; Günay D; Cagatay P; Ozcan R; Büyükdevrim AS
Obes Surg; 2003 Oct; 13(5):699-705. PubMed ID: 14627463
[TBL] [Abstract][Full Text] [Related]
51. From obesity to diabetes.
Keller U
Int J Vitam Nutr Res; 2006 Jul; 76(4):172-7. PubMed ID: 17243079
[TBL] [Abstract][Full Text] [Related]
52. Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance.
Shoelson SE; Lee J; Yuan M
Int J Obes Relat Metab Disord; 2003 Dec; 27 Suppl 3():S49-52. PubMed ID: 14704745
[TBL] [Abstract][Full Text] [Related]
53. The Role of Vitamin D and Its Molecular Bases in Insulin Resistance, Diabetes, Metabolic Syndrome, and Cardiovascular Disease: State of the Art.
Argano C; Mirarchi L; Amodeo S; Orlando V; Torres A; Corrao S
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895163
[TBL] [Abstract][Full Text] [Related]
54. Therapeutic approaches to target inflammation in type 2 diabetes.
Goldfine AB; Fonseca V; Shoelson SE
Clin Chem; 2011 Feb; 57(2):162-7. PubMed ID: 21098138
[TBL] [Abstract][Full Text] [Related]
55. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes.
Goldfine AB; Silver R; Aldhahi W; Cai D; Tatro E; Lee J; Shoelson SE
Clin Transl Sci; 2008 May; 1(1):36-43. PubMed ID: 19337387
[TBL] [Abstract][Full Text] [Related]
56. Inflammation and insulin resistance.
Shoelson SE; Lee J; Goldfine AB
J Clin Invest; 2006 Jul; 116(7):1793-801. PubMed ID: 16823477
[TBL] [Abstract][Full Text] [Related]
57. [Chronic mild inflammation links obesity, metabolic syndrome, atherosclerosis and diabetes].
Andel M; Polák J; Kraml P; Dlouhý P; Stich V
Vnitr Lek; 2009; 55(7-8):659-65. PubMed ID: 19731872
[TBL] [Abstract][Full Text] [Related]
58. The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes.
Mikhailidis DP; Press M
Expert Opin Pharmacother; 2007 Dec; 8(17):3009-20. PubMed ID: 18001259
[TBL] [Abstract][Full Text] [Related]
59. Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease.
Ladeiras-Lopes R; Fontes-Carvalho R; Bettencourt N; Sampaio F; Gama V; Leite-Moreira A
Expert Opin Ther Targets; 2015 Jul; 19(7):869-77. PubMed ID: 25762117
[TBL] [Abstract][Full Text] [Related]
60. Cardiovascular disease and modifiable cardiometabolic risk factors.
Cannon CP
Clin Cornerstone; 2008; 9(2):24-38; discussion 39-41. PubMed ID: 19410160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
